✦ LIBER ✦

Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer

✍ Scribed by Horak, C. E.; Pusztai, L.; Xing, G.; Trifan, O. C.; Saura, C.; Tseng, L.-M.; Chan, S.; Welcher, R.; Liu, D.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Doxorubicin/Pemetrexed Followed by Docet

✍ Andreas Schneeweiss; Ilka Lauschner; Amparo Ruiz; Angel Guerrero; Pedro Sánchez- 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 88 KB

A Feasibility Study of Bevacizumab plus

✍ Sikov, W.M.; Sinclair, N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 63 KB

57 Neoadjuvant doxorubicin/cyclophospham

✍ M. Tokar; M. Koretz; T. Hertz; O. Bloshitski; B. Delgado; N. Sion-Vardy; S. Aria 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Adjuvant dose-dense doxorubicin plus cyc

✍ Nicholas Robert; Lea Krekow; Chris Stokoe; Alicia Clawson; Jose Iglesias; Joyce 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 199 KB

Doxorubicin and cyclophosphamide followe

✍ Laura G. Estevez; José Luis Fortes; Encarna Adrover; Gloria Peiró; Mireia Margel 📂 Article 📅 2009 🏛 Springer Milan 🌐 Spanish ⚖ 244 KB

Phase II Study of Neoadjuvant Docetaxel/

✍ Steven A. Limentani; Adam M. Brufsky; John K. Erban; Mohammed Jahanzeb; Deborah 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 490 KB